Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06933381 · ClinicalTrials.gov registry record · NA

Vapocoolant Spray to Reduce Pain With Nexplanon Insertion

A NA study of Reducing Pain With Nexplanon Implant Insertion, sponsored by Queen's Medical Center.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
3
Study locations

NCT06933381 is a NA study of Reducing Pain With Nexplanon Implant Insertion that is actively recruiting participants, run by Queen's Medical Center. The registered enrollment target is 70 participants. The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06933381, a NA study of Reducing Pain With Nexplanon Implant Insertion, is actively recruiting participants, sponsored by Queen's Medical Center.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.

Interventions

  • OTHER Placebo
  • DEVICE Vapocoolant spray

Study Locations (3)

Hawaii

  • Queens Medical Center POB 2 Suite 402 - Honolulu
  • Queens Medical Center POB1 Clinic 1004 - Honolulu
  • Women's Center Queen's North Hawai'i Community Hospital Suite #124 and #120 - Waimea

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-06-16
Est. Completion 2026-05-01
Phase NA

Sponsor

Queen's Medical Center

17 total trials

What the Registry Record Tells You About NCT06933381

The ClinicalTrials.gov registry entry for NCT06933381 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Queen's Medical Center, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Reducing Pain With Nexplanon Implant Insertion appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06933381 reports 3 study locations spanning 1 distinct geographic area - top geographies include Hawaii.

Frequently Asked Questions

What is clinical trial NCT06933381 about?

NCT06933381 is a clinical study titled "Vapocoolant Spray to Reduce Pain With Nexplanon Insertion". The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.

What is the current status of trial NCT06933381?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-06-16. Estimated completion is 2026-05-01.

What conditions does trial NCT06933381 study?

This clinical trial studies the following conditions: Reducing Pain With Nexplanon Implant Insertion.

What interventions are being tested in trial NCT06933381?

The interventions under investigation include: Placebo (OTHER), Vapocoolant spray (DEVICE).

Who is sponsoring clinical trial NCT06933381?

This trial is sponsored by Queen's Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06933381 being conducted?

This trial has 3 study locations across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.